NKTR News and Press, Nektar Therapeutics From 09/06/23

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th PR Newswire SAN FRANCISCO , Sept. 6, 2023 /...

2023-09-04 04:30:00 ET Summary For the week, the S&P 500 was up 2.5%. We are now just 1.6% below the 2023 high-water mark, set on July 31. The market entered a Golden Cross configuration on February 2, 2023. A recession remains a distinct possibility, especially if the Fed...

2023-08-21 06:45:00 ET Summary After making a new 2023 high on July 31, the market is now in the process of consolidating its gains and expanding its participation. The best performer last week was Volatility, as investors looked for ways to protect their gains from further downsi...

2023-08-14 13:30:00 ET Summary After making a new 2023 high on July 31, the market is now in the process of consolidating its gains and expanding its participation. The Death Cross ended on February 2, 2023. We are now in a Golden Cross configuration, with the 50-day above the 200...

2023-08-11 08:16:36 ET Cano Health ( CANO ) -48% after Q2 earning release . Yield10 Bioscience ( YTEN ) -46% . Maxeon Solar Technologies, Ltd. ( MAXN ) -26% after Q2 earning release . LQR House ( LQR ) -17% . Vistagen Therapeutics ( ...

2023-08-09 08:32:37 ET Tigo Energy ( TYGO ) -37% reports record revenues and gross profit for second quarter 2023. Bruush Oral Care ( BRSH ) -29% . Fitell Corporation ( FTEL ) -26% . Veritone ( VERI ) -26% after Q2 earning release . ...

2023-08-08 22:58:10 ET Nektar Therapeutics (NKTR) Q2 2023 Earnings Conference Call August 8, 2023, 5:00 PM ET Company Participants Vivian Wu - Director, Investor Relations and Corporate Affairs Howard Robin - President and CEO Dr. Jonathan Zalevsky - Chief, Resea...

2023-08-08 17:00:29 ET Nektar Therapeutics press release ( NASDAQ: NKTR ): Q2 GAAP EPS of -$0.27 beats by $0.01 . Revenue of $20.5M (-5.1% Y/Y) misses by $1.33M . Cash and investments in marketable securities at June 30, 2023, were $409.4 million as compared to...

Nektar Therapeutics Reports Second Quarter 2023 Financial Results PR Newswire SAN FRANCISCO , Aug. 8, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023 . Cash an...

2023-08-08 13:05:05 ET Summary Eli Lilly and Company's Q2 2023 earnings were boosted by strong sales growth of three key products in its pipeline: Verzenio, Jardiance, and Mounjaro. Verzenio, a breast cancer drug, saw significant sales growth due to its approval for multiple indic...